← Markets

Astrana Health, Inc.

ASTH · NASDAQ

Market closed$44.94$-0.160000 (-0.35%)After hours $45.69 · +1.67%

Key statistics

Previous close$45.10
Open$44.43
Day high$45.00
Day low$43.05
52-week high$51.60
52-week low$18.08
Market cap2.23B
Volume675.58K
Average volume589.75K
P/E ratio30.36
Forward P/E—
EPS1.48
Dividend yield0.00%

Market context

Why it moved

ASTH experienced a modest decline today, likely due to mild profit-taking and general market pressure, as no major company-specific catalysts were identified, though analyst bullish sentiment and the stock's strong year-to-date performance continue to keep losses contained.

QuiverquantMarketbeatYelpInstagramSimplywall

What is happening

Recent company-specific developments and publisher coverage.

July 16, 2026Astrana Health fell sharply, underperforming the broader healthcare sector (XLV down ~0.3%), as the stock gave back gains from earlier in the week. The decline came despite recent positive catalysts—including ACO-driven $120.4M in Medicare shared savings, two strategic leadership appointments on July 13, and a scheduled Q2 earnings call for August 6—with broader sector headwinds from HCA Healthcare's profit forecast cut and rising concerns over uninsured patient volumes weighing on care facilities peers. UnitedHealth's strong Q2 beat provided some sector lift, but hospital and care facility names faced pressure from elevated labor costs and Medicaid coverage losses.

-4.1241

July 16, 2026Astrana Health fell sharply, pressured by sector-wide headwinds as peer HCA Healthcare cut its 2026 profit outlook due to a surge in uninsured patients following Obamacare coverage losses, dragging hospital and care facility stocks broadly lower. The decline came despite two positive company-specific developments: Astrana announced its Q2 2026 earnings call for August 6 and named two senior executives—Daniel Rothman as President of Physician Enterprise and Vishal Gupta as SVP of Enterprise Transformation—to accelerate its AI-enabled, value-based care platform.

-4

July 15, 2026Astrana Health rose nearly 3% as investors responded to a pair of bullish catalysts: the company scheduled its Q2 2026 earnings call for August 6 and announced two senior executive appointments—Daniel Rothman as President of Physician Enterprise and Vishal Gupta as SVP of Enterprise Transformation—signaling continued investment in scaling its AI-enabled value-based care platform. The gains extended recent momentum following strong Q1 results (56% YoY revenue growth) and a BTIG price target raise to $65, with the healthcare sector providing a constructive backdrop amid a broader soft-CPI-driven market rally.

2.8547

July 14, 2026Astrana Health closed modestly higher, outperforming a broadly pressured healthcare sector (XLV) as the company released two significant catalysts: its ACOs delivered $120.4 million in gross shared savings in 2024 with all eight achieving net savings, and the company bolstered its leadership team with key AI-focused hires. With Q1 2026 revenue up 56% year-over-year and $3.18B in FY2025 revenue, Astrana's value-based care platform continues to gain investor confidence even as broader healthcare faces sector-wide earnings headwinds and macro uncertainty from U.S.-Iran tensions lifting oil prices.

1.6212

July 11, 2026Astrana Health closed essentially flat as investors weigh a stretched valuation against strong sector momentum. The stock trades at a P/E of roughly 76x—well above the healthcare industry average of ~25x—raising execution risk concerns even as value-based care tailwinds remain intact. The broader healthcare sector has shown notable relative strength, with 91% of S&P 500 healthcare stocks outperforming recently, while the XLV ETF held near its session lows in after-hours trading. In after-hours activity, Astrana shares slipped ~1.7%, adding near-term pressure ahead of the Q2 earnings season, which analysts view as a key test for whether the stock's premium multiple can be sustained.

0.1389

July 9, 2026Astrana Health closed modestly higher, benefiting from continued momentum in the healthcare sector, which has been among the market's top performers for two consecutive weeks. A Barclays upgrade to Overweight with a $50 price target—citing improving value-based care dynamics, stabilizing cost trends, and a favorable 2027 Medicare Advantage rate outlook—has been a key catalyst, alongside analyst consensus projections for Q2 earnings growth of ~74% year-over-year. While valuation concerns linger at ~75x P/E, the Prospect integration and expanding full-risk membership remain central to the bull case.

1.1452

July 8, 2026Astrana Health declined during the regular session amid a broader market risk-off move triggered by renewed U.S.-Iran military exchanges and surging oil prices, though shares recovered partially in after-hours trading. The pullback comes just days after a Barclays upgrade to Overweight with a $50 price target, citing an improved value-based care outlook and favorable 2027 Medicare Advantage rate expectations, and ahead of Q2 earnings where analysts project EPS growth of ~74% year-over-year — suggesting the dip may reflect macro headwinds rather than company-specific concerns.

-1.6156

July 7, 2026Astrana Health closed essentially flat as investors digested a notable Barclays upgrade to Overweight with a raised price target of $50 (from $37), citing an improved value-based care outlook, stabilizing medical cost trends, and a more favorable 2027 Medicare Advantage rate environment. The company is also navigating a CFO-level accounting leadership transition — with Glenn Sobotka retiring in August and John Vong stepping in — while analyst consensus now projects Q2 EPS growth of ~74% year-over-year and revenue up ~50%, keeping near-term earnings expectations elevated ahead of results.

0.2771

Simply Wall Street · July 14, 2026Astrana Health (ASTH) Faces A Valuation Test As ACO Savings And Growth Come Into FocusStock Titan · July 14, 2026Astrana Health Schedules Aug. 6 Call on Second-Quarter ResultsStock Titan · July 13, 2026New Astrana Health leaders tasked with scaling its AI-enabled care platformPR Newswire · July 13, 2026Astrana Health ACOs Deliver $120.4 Million in Gross Shared Savings in 2024 Performance YearPR Newswire · July 13, 2026Astrana Health Strengthens Leadership Team to Accelerate Long-Term GrowthSimply Wall Street · July 5, 2026Is Astrana Health’s (ASTH) CFO Transition Quietly Reframing Its Value-Based Care Risk Profile?PR Newswire · June 4, 2026Astrana Health Named to the 2026 Fortune 1000 List Following Strong Revenue GrowthStockStory · November 7, 2025Why Astrana Health (ASTH) Shares Are Plunging Today
Benzinga · July 14, 2026TD Cowen Maintains Buy on Astrana Health, Raises Price Target to $50
Benzinga · July 14, 2026BTIG Maintains Buy on Astrana Health, Raises Price Target to $65
Mt Newswire · July 2, 2026Astrana Health Chief Accounting Officer to Retire
Benzinga · May 26, 2026Barclays Upgrades Astrana Health to Overweight, Raises Price Target to $50
Benzinga · May 14, 2026Truist Securities Maintains Buy on Astrana Health, Raises Price Target to $47
Mt Newswire · May 14, 2026Truist Securities Adjusts Price Target on Astrana Health to $47 From $38, Maintains Buy Rating
Benzinga · May 12, 2026TD Cowen Maintains Buy on Astrana Health, Raises Price Target to $45
Benzinga · May 11, 2026Physician Association Of California And Astrana Health Collaborate To Help Independent Primary Care Physicians Remain Independent In Complex Healthcare System

Peers

S&P 500SPX · $7,457.69-1.01%Privia Health Group, Inc.PRVA · $26.90-1.18%Agilon Health, Inc.AGL · $129.84+7.11%Pediatrix Medical Group, Inc.MD · $26.13-0.80%OPKO Health, Inc.OPK · $1.190.00%NeoGenomics, Inc.NEO · $14.61-1.55%The Pennant Group, Inc.PNTG · $41.95+0.58%HCA Healthcare, Inc.HCA · $371.18-3.77%Tenet Healthcare CorporationTHC · $194.91-2.15%Universal Health Services, Inc.UHS · $151.16-1.55%DaVita Inc.DVA · $236.97+1.26%The Ensign Group, Inc.ENSG · $171.28-0.93%